Evaluation of Oral Antidiabetic Dosing and Drug Interactions in Type 2 Diabetic Patients

https://doi.org/10.22146/jmpf.33263

Nova Hasani Furdiyanti(1*), Fania Putri Luhurningtyas(2), Ratna Sari(3), Yulianti Yulianti(4)

(1) Study Program of Pharmacy, Ngudi Waluyo University
(2) Study Program of Pharmacy, Ngudi Waluyo University
(3) Study Program of Pharmacy, Ngudi Waluyo University
(4) Study Program of Pharmacy, Ngudi Waluyo University
(*) Corresponding Author

Abstract


Indonesia is listed as the country with the highest type 2 diabetes mellitus patients number 4 in the world. Accuracy of treatment is necessary in the success of therapy for type 2 diabetes mellitus patients. Inaccurate dosage or drug interaction events can lead to treatment failure or even cause adverse effects in patients. Patients with type 2 diabetes mellitus usually have comorbidities that tend to get therapy with many drugs, thus increasing the risk of drug interactions. Drug interactions with oral antidiabetes are known to exist that can be life-threatening. The aim of this research is to know the accuracy of dose of oral antidiabetika drug and drug interaction event in type 2 diabetes mellitus patient. This research is a descriptive retrospective observational study. Data collection is done retrospectively, and sampling method is purposive sampling. Research subjects were all inpatients of type 2 diabetes mellitus 26 - 65 years old, who received oral antidiabetes therapy period 2016 at RS Sultan Agung Semarang, and meet the criteria of inclusion and exclusion. The data analyzed the incidence of drug interaction and dosage accuracy (based on dose parameter and frequency of administration). The results of the study in 86 subjects showed that the most widely used single therapy was metformin (50,98%) while the most used combination therapy was metformin and glimepiride (57,14%) .The incidence of drug interaction was 5%, between glimepiride and aspirin with a pharmacokinetic mechanism occurring in 4 patients. The percentage of inaccurate doses of oral antidiabetic drugs was 3.5%, which occurred in patients taking metformin and acarbose.

Keywords


oral antidiabetic; type 2 diabetes mellitus; dosage; drug interaction

Full Text:

PDF


References

Al-Mukhtar, S.B., Fadhil, N.N., dan Hanna, B.E., 2012. General and gender characteristics of type 2 diabetes mellitus among the younger and older age groups. Oman Medical Journal, 27: 375–382.

Berry, C., Tardif, J.-C., dan Bourassa, M.G., 2007. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. Journal of the American College of Cardiology, 49: 631–642.

Bjerrum, L., Andersen, M., Petersen, G., dan Kragstrup, J., 2003. Exposure to potential drug interactions in primary health care. Scandinavian Journal of Primary Health Care, 21: 153–158.

Boyle, J.P., Thompson, T.J., Gregg, E.W., Barker, L.E., dan Williamson, D.F., 2010. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics, 8: 29.

Cheekurthy, A.J.P., Rambabu1, C., dan Kumar, A., 2016. Prevalence of Type 2 Diabetes Mellitus among Women and the Associated Risk Factors. Research & Reviews: Journal of Nursing and Health Sciences, 2: 1–5.

Duong, J.K., Roberts, D.M., Furlong, T.J., Kumar, S.S., Greenfield, J.R., Kirkpatrick, C.M., dkk., 2012. Metformin therapy in patients with chronic kidney disease. Diabetes, Obesity and Metabolism, 14: 963–965.

Hassan, M.H. dan Abd-Allah, G.M., 2015. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Pakistan Journal of Pharmaceutical Sciences, 28: 1723–1730.

Hirst, J.A., Farmer, A.J., Ali, R., Roberts, N.W., dan Stevens, R.J., 2012. Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control. Diabetes Care, 35: 446–454.

Kroon, L.A. dan Williams, C., 2013. Diabetes Mellitus, dalam: Applied Therapeutics, The Clinical Use of Drugs. Lippincott Williams & Wilkins, Philadelphia.

Lacy, C.F., Armstrong, L., Goldman, M.P., dan Lance, L.L., 2014. Drug Information Handbook, 17th ed. Lexi-Comp, Incorporated, Amerika.

Lira, C.P., Widya, A.L., dan Wewengkang, D.S., 2017. Potensi Drug Related Problems (Drps) Penggunaan Obat Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 Di Instalasi Rawat Inap Rumah Sakit Kalooran Gmim Amurang. Pharmacon, 6: .

Mogul, H., Freeman, R., dan Nguyen, K., 2016. Metformin-Sustained Weight Loss And Reduced Android Fat Tissue At 12 Months In Empowir (Enhance The Metabolic Profile Of Women With Insulin Resistance): A Double Blind, Placebo-Controlled, Randomized Trial Of Normoglycemic Women With Midlife Weight Gain. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22: 575–586.

Nazilah, K., Rachmawati, E., dan Subagijo, P.B., 2017. Identifikasi Drug Related Problems (DRPs) pada Terapi Diabetes Melitus Tipe 2 di Instalasi Rawat Inap RSD dr. Soebandi Jember Periode Tahun 2015 (Identification of Drug Related Problems (DRPs) for Type 2 Diabetes Mellitus Therapy in Hospitalized Patients. Pustaka Kesehatan, 5: .

Notoatmodjo, S., 2015. Metodologi Penelitian Kesehatan. Rineka Cipta, Jakarta.

Nye, H.J. dan Herrington, W.G., 2011. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron. Clinical Practice, 118: c380–383.

Patel, P.S., Rana, D.A., Suthar, J.V., Malhotra, S.D., dan Patel, V.J., 2014. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. Journal of Basic and Clinical Pharmacy, 5: 44–48.

Peck, R., 2018. Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient. Annual Review of Pharmacology and Toxicology, 58: null.

Pernicova, I. dan Korbonits, M., 2014. Metformin--mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology, 10: 143–156.

Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., dkk., 2008. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 117: e25–146.

Tatro, D.S., 2012. Drug Interaction Facts 2015. Lippincott Williams & Wilkins.

Tornio, A., Niemi, M., Neuvonen, P.J., dan Backman, J.T., 2012. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences, 33: 312–322.



DOI: https://doi.org/10.22146/jmpf.33263

Article Metrics

Abstract views : 4051 | views : 24281

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats